The Single Pass Kronos device being used for a kidney biopsy procedure in Rome, Italy. Credit: Single Pass, Inc./ PRNewswire.

Single Pass has announced that its Kronos biopsy closure device, a Class II medical device, has received clearance from the US Food and Drug Administration (FDA).

The FDA has confirmed that the device is substantially equivalent to its predicate devices in terms of safety and effectiveness.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

With this clearance, the device can now be available for commercial use in the country.

The Single Pass team collaborated with its contract manufacturing partner, M4D, to bring the closure device to market.

The device has also achieved the CE Mark under the EU MDR regulations, further solidifying its presence in the international market.

See Also:

Mermaid Medical, Single Pass’s US distribution partner, is set to commence sales within the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Single Pass co-founder and CEO Bill Colone said: “We are thrilled to have received FDA clearance for our Kronos biopsy closure device. The Kronos device represents a significant advancement, offering healthcare professionals a reliable and efficient solution for post-biopsy bleeding and improved patient care.”

The partnership aims to provide immediate national access to the Kronos device, which is expected to benefit patients and healthcare providers across the country through its unique technology.

In February 2024, Single Pass reported the completion of the first live clinical cases in Italy using the Kronos biopsy closure device.

The procedures, which took place at the Universitario Campus Bio Medico and Fondazione Policlinico in Rome, demonstrated the device’s ability to transform biopsy procedures by ensuring precise closure post-biopsy.

The first case involved a kidney biopsy where a 22cm Kronos device was used in conjunction with a 13cm biopsy needle.

The device achieved successful cauterisation and the depth gauge provided accurate targeting.

Earlier this year, the company entered an exclusive distribution agreement with Mermaid Medical Group to introduce the advanced biopsy closure device to the US market.